Related Experiment Video

Updated: Apr 19, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

10.3K

Anti-vascular endothelial growth factor therapy in breast cancer

Tina Bøgelund Kristensen1, Malin L T Knutsson2, Markus Wehland3

  • 1Department of Biomedicine, Pharmacology, Aarhus University, Wilhelm Meyers Allé 4, Aarhus C 8000, Denmark. tinakristensen@studmed.au.dk.

International Journal of Molecular Sciences
|December 17, 2014
PubMed

Insights

Anti-angiogenic drugs targeting the vascular endothelial growth factor system show unconvincing efficacy in advanced breast cancer. Further research and biomarkers are needed to identify suitable patients for these cancer therapies.

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Neo-angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.
  • Targeting the vascular endothelial growth factor (VEGF) system is a key strategy in anti-cancer therapy.

Purpose of the Study:

  • To review the efficacy of three anti-angiogenic agents (bevacizumab, ramucirumab, sorafenib) targeting the VEGF system in advanced breast cancer.
  • To assess the role of these agents in adjuvant and neo-adjuvant settings.

Main Methods:

  • Review of clinical trials evaluating anti-angiogenic drugs in advanced breast cancer.
  • Analysis of treatment outcomes and tumor response variability.

Main Results:

  • Observed clinical improvements with anti-angiogenic drugs in advanced breast cancer have been unconvincing to date.
  • Outcomes of anti-angiogenic therapy show significant variability in tumor response.

Conclusions:

  • Further research is required to establish the efficacy of anti-angiogenic drugs in breast cancer treatment.
  • Development of biomarkers and molecular profiling is essential to identify patients who will benefit from anti-angiogenic therapy, improving cost-effectiveness.

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:21

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

110
Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

3.1K

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
4.0K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
583
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K